Dr. Winnie Wanjiku Mwangi
Clinical Pharmacist (Oncology), Head of Clinical Pharmacy – KUTRRH
Vice Chair – OPSOK
Quick Facts
- Experience: 10+ years in oncology and clinical pharmacy
- Current Role: Head of Clinical Pharmacy - KUTRRH
- Key Achievement: 2023 ISOPP Pfizer Grant Recipient
- Specialty: Biosimilars Implementation Research
Pioneering Oncology Pharmacy Excellence
Dr. Mwangi's innovative leadership in biosimilars research and clinical pharmacy services is transforming cancer care delivery across Kenya's leading teaching hospitals.
Professional Overview
Dr. Winnie Wanjiku Mwangi is a highly accomplished clinical pharmacist who has dedicated over a decade to advancing oncology care in Kenya. As Head of Clinical Pharmacy at Kenyatta University Teaching, Referral & Research Hospital (KUTRRH), she leads one of the country's most innovative clinical pharmacy programs.
Her pioneering work spans from establishing oncology units in underserved regions to conducting cutting-edge research on biosimilars implementation. Dr. Mwangi's commitment to multidisciplinary care and evidence-based practice has positioned her as a leading voice in East African oncology pharmacy.
Leadership & Clinical Excellence
Clinical Pharmacy Leadership
Heads KUTRRH's comprehensive clinical pharmacy department, overseeing pharmaceutical care for complex oncology cases
Oncology Unit Development
Instrumental in establishing the oncology unit at Meru Teaching and Referral Hospital, expanding cancer care access
Medication Therapy Management
Led operationalization of MTM clinics, ensuring optimal therapeutic outcomes for cancer patients
Anticoagulation Services
Established specialized anticoagulation clinics, providing critical supportive care for oncology patients
2023 ISOPP Pfizer Grant Recipient
Awarded prestigious international grant for groundbreaking research on biosimilars implementation at KUTRRH, advancing affordable cancer treatment options for Kenyan patients.
International Collaboration & Research
ISOPP Research Committee Member
CurrentActive contributor to international oncology pharmacy research initiatives, focusing on evidence-based practice improvements.
ISOPP Biosimilars Taskforce
CurrentKey member of specialized taskforce developing global guidelines for biosimilar implementation in oncology practice.
Biosimilars Implementation Research
2023-PresentLeading comprehensive study on biosimilars adoption at KUTRRH, with implications for healthcare affordability across Africa.
Meru Oncology Unit Establishment
Previous RolePlayed pivotal role in developing oncology services at Meru Teaching and Referral Hospital, expanding regional cancer care capacity.
Professional Memberships & Engagement
Dr. Mwangi maintains active involvement in key professional organizations, contributing to policy development and knowledge sharing:
Through these memberships, she regularly presents at national and regional oncology forums, sharing insights on clinical pharmacy innovations, biosimilars implementation, and multidisciplinary cancer care approaches.
Research Focus: Biosimilars in Oncology
Dr. Mwangi's research on biosimilars represents a critical contribution to making cancer treatment more accessible and affordable in resource-limited settings. Her work at KUTRRH focuses on:
- Clinical Outcomes Assessment: Evaluating the efficacy and safety of biosimilar oncology medications compared to reference biologics
- Healthcare Economic Impact: Analyzing cost savings and budget impact of biosimilar adoption in public healthcare systems
- Implementation Frameworks: Developing protocols for safe and effective biosimilar switching in oncology practice
- Healthcare Provider Education: Creating training programs to ensure confident biosimilar prescribing and dispensing
- Patient Education Initiatives: Developing resources to improve patient understanding and acceptance of biosimilar therapies
Vision for Oncology Pharmacy
As Vice Chair of OPSOK, Dr. Mwangi champions several key initiatives that reflect her vision for the future of oncology pharmacy in Kenya:
Multidisciplinary Integration: Promoting seamless collaboration between pharmacists, oncologists, nurses, and other healthcare professionals to optimize patient outcomes through coordinated care approaches.
Evidence-Based Innovation: Advancing research that directly impacts clinical practice, with particular focus on treatments that improve both patient outcomes and healthcare affordability.
Service Expansion: Developing specialized pharmacy services like medication therapy management and anticoagulation clinics that address the complex needs of cancer patients.
Regional Leadership: Positioning Kenya as a leader in oncology pharmacy research and practice, with particular expertise in biosimilars and cost-effective cancer care delivery.
Transforming Cancer Care Through Innovation
"Our focus on biosimilars research and multidisciplinary care models is not just about improving treatment options – it's about making life-saving cancer therapies accessible to every patient who needs them."
